COLUMBIA, Md., Sept. 8 Martek Biosciences Corporation (Nasdaq: MATK) announced today that a panel of judges on the United States Court of Appeals for the Federal Circuit has ruled in Martek's favor in appeal proceedings related to a patent infringement lawsuit between Martek and Lonza, Ltd., Nutrinova Inc. and Nutrinova Nutrition Specialties & Food Ingredients GmbH (collectively "Lonza"). The appeals involve Lonza's U.S. sale and use of DHA in functional foods and dietary supplements and do not involve Martek's core infant formula patents. Lonza has the right to request a re-hearing.
Advertisement
These rulings represent an across-the-board victory for Martek as the Federal Circuit ruled in Martek's favor on all four of the patents in question. While two of the patents at issue have now expired, two others have expiration dates in August 2011 and December 2014, respectively. More specifically, the Federal Circuit 1) upheld a Martek patent directed to certain fermentation methods used to produce fatty acids such as DHA and 2) reversed the trial court's interpretation of certain claim language directed to methods of increasing the concentration of microbial omega-3 fatty acids such as DHA in an animal. While the lower court construed the term 'animal' to exclude humans, the Federal Circuit concluded that the term 'animal' does include humans and remanded the patent to the trial court for further proceedings consistent with this interpretation. This Federal Circuit decision is further evidence of the strength of the Martek patents at issue, which include claims covering food and dietary supplement applications for human consumption. Martek is the only manufacturer and supplier of algal DHA to the U.S. food and dietary supplements industry and is a leading worldwide supplier with its flagship brand, life'sDHA(TM).
Advertisement
"Martek's policy is to vigorously defend its patent portfolio and these rulings demonstrate the value of this approach," said Steve Dubin, CEO of Martek Biosciences. "Martek's strategy continues to be to develop multiple layers of patent protection. Today our patent portfolio protecting our products and ideas includes more than 700 granted patents and pending applications worldwide."
Martek Biosciences Corporation (Nasdaq: MATK) is a leader in the innovation and development of omega-3 DHA products that promote health and wellness through every stage of life. The Company produces life'sDHA(TM), a vegetarian source of the omega-3 fatty acid DHA (docosahexaenoic acid), for use in foods, infant formula and supplements, and life'sARA(TM) (arachidonic acid), an omega-6 fatty acid, for use in infant formula. For more information on Martek Biosciences, visit www.martek.com.
Sections of this release contain forward-looking statements. These statements are based upon numerous assumptions which Martek cannot control and involve risks and uncertainties that could cause actual results to differ. These statements should be understood in light of the risk factors set forth in the company's filings with the Securities and Exchange Commission, including, but not limited to, the company's Form 10-K for the fiscal year ended October 31, 2008 and other filed reports on Form 10-K, Form 10-K/A, Form 10-Q and Form 8-K.
Contact: Cassie France-Kelly Public Relations, Martek (443) 542-2116 [email protected] Kyle Stults Investor Relations, Martek (410) 740-0081 [email protected]
SOURCE Martek Biosciences Corporation
